Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Background Hyperthermic intraperitoneal (IP) chemotherapy after cytoreduction improves survival in patients with colorectal carcinomatosis of the peritoneal surface. Most protocols use single agents (mitomycin C or oxaliplatin) provided IP. The purpose of this study was to determine whether combination IP chemotherapy is superior to single-agent therapy in a mouse model. Methods Nu/Nu mice were injected IP with HT-29 colorectal cancer cells. Animals were treated with single agents or combinations. Primary end point was overall survival. Agents explored included oxaliplatin, mitomycin C, panitumumab, erlotinib, cetuximab, and irinotecan delivered IP as single agents; mitomycin C, panitumumab, and irinotecan in combination IP; and 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) in combination delivered intravenously. Results Survival of mice receiving irinotecan or mitomycin C IP was greater than controls. Median survival of mice receiving intravenous FOLFIRI was also greater than control. However, survival of mice receiving IP irinotecan or mitomycin C was far greater than mice receiving intravenous FOLFIRI. For combination therapy, a positive interaction was observed with mitomycin C and irinotecan, whereas survival was greater than either agent individually. No interaction was observed between panitumumab and mitomycin C or irinotecan. However, an overall survival benefit was observed with the combination of irinotecan, mitomycin C, and panitumumab; at 120 days after cell inj…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combination therapy comprising MMC has improved animal model outcomes and shown additional survival benefits for CC patients [7].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [7]
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“instead, mutation in the downstream signaling mediator, KRAS, predicted outcome such that disease of patients with activating mutations of KRAS did not respond to panitumumab.(35) Subsequent studies have further demonstrated that mutational status of several molecules in the EGFR signaling cascade, including PI3KCA an…”
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Sadeghi, B., Arvieux, C., Glehen, O., Beaujard, A. C., Rivoire, M., Baulieux, J., Fontaumard, E., Brachet, A., Caillot, J. L., Faure, J. L., et al. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o · Cited by 1,200
Glehen, O., Kwiatkowski, F., Sugarbaker, P. H., Elias, D., Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.012 · Cited by 1,184 · cited 5×
“This study further had a trend toward higher survival rates in patients receiving both hyperthermic therapy during surgery together with postoperative IP therapy compared with patients receiving either treatment alone.(11) Although these differences were not statistically significant, this finding may indicate that mu…”
Influential(2011) · Hepatogastroenterology · doi:10.5754/hge11069 · Cited by 1,140
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9966-2 · Cited by 1,033 · cited 4×
“This viewpoint has been supported by reports documenting median survival of patients with peritoneal dissemination to be between 5.2 and 7 months.5–7 Previously presented as an oral presentation at SSO’s 62nd Annual Cancer Symposium, March 5–8, 2009, Phoenix, AZ. Society of Surgical Oncology 2009 First Received: 4 Mar…”
InfluentialThe Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/7800.16189 · Cited by 881
Elias, D., Lefevre, J. H., Chevalier, J., Brouquet, A., Marchal, F., Classe, J.-M., Ferron, G., Guilloit, J.-M., Meeus, P., Goéré, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7160 · Cited by 876
Peritoneal carcinomatosis from colorectal cancer
Jayne, D. G., Fook, S., Loi, C., & Seow-Choen, F. (2002) · British Journal of Surgery · doi:10.1046/j.1365-2168.2002.02274.x · Cited by 831
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688 · cited 1×
“Although early-stage disease demonstrates satisfactory outcomes with standard surgical resection, once disease spreads outside the bowel wall, survival decreases dramatically, with stage IV patients expected to have a median survival of approximately 20 months with optimal therapy.(3,4) Most tumors will spread to the…”
Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors
Chu, D. Z. J., Lang, N. P., Thompson, C., Osteen, P. K., & Westbrook, K. C. (1989) · Cancer · doi:10.1002/1097-0142(19890115)63:2<364::aid-cncr2820630228>3.0.co;2-v · Cited by 598
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593 · cited 1×
“At the time the animals were killed, ascites was collected with a 1-mL syringe with an 18-gauge needle, and tumor load and distribution were assessed as previously described.(29)”
Self-citationJhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · cited 2×
“Importantly, the human CRC cells HT-29 used in the present studies, although expressing wild-type KRAS, express a mutant BRAF and have been shown to exhibit limited responsiveness to cetuximab.(36) It is interesting to note that although HT-29 cells express mutant BRAF, the triple-agent therapy examined in this study,…”
Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337
Yan, T. D., Welch, L., Black, D., & Sugarbaker, P. H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl428 · Cited by 308
Sugarbaker, P. H., Graves, T., DeBruijn, E. A., Cunliffe, W. J., Mullins, R. E., Hull, W. E., Oliff, L., & Schlag, P. (1990) · PubMed · Cited by 280
Foon, K. A., Yang, X.-D., Weiner, L. M., Belldegrun, A. S., Figlin, R. A., Crawford, J., Rowinsky, E. K., Dutcher, J. P., Vogelzang, N. J., Gollub, J., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.098 · Cited by 218
Esquivel, J., Elias, D., Baratti, D., Kusamura, S., & Deraco, M. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21053 · Cited by 198 · cited 1×
“Although early-stage disease demonstrates satisfactory outcomes with standard surgical resection, once disease spreads outside the bowel wall, survival decreases dramatically, with stage IV patients expected to have a median survival of approximately 20 months with optimal therapy.(3,4) Most tumors will spread to the…”
Levin, B., Brooks, D., Smith, R. A., & Stone, A. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.44 · Cited by 193 · cited 1×
“mately 50,000 deaths, ranking it second for cancer-related deaths.(1,2) Although early-stage disease demonstrates satisfactory outcomes with standard surgical resection, once disease spreads outside the bowel wall, survival decreases dramatically, with stage IV patients expected to have a median survival of approximat…”
Targeting the EGFR Pathway for Cancer Therapy
Johnston, J., Navaratnam, S., Pitz, M., Maniate, J., Wiechec, E., Baust, H., Gingerich, J., Skliris, G., Murphy, L., & Los, M. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706779026174 · Cited by 183
Cunliffe, W. J., & Sugarbaker, P. H. (1989) · British journal of surgery · doi:10.1002/bjs.1800761030 · Cited by 166
Peritoneal carcinomatosis of colorectal origin
Elias, D., Raynard, B., Farkhondeh, F., Goéré, D., Rouquie, D., Ciuchendea, R., Pocard, M., & Ducreux, M. (2006) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(06)73512-6 · Cited by 165
Thermal Enhancement of New Chemotherapeutic Agents at Moderate Hyperthermia
Mohamed, F., Marchettini, P., Stuart, O. A., Urano, M., & Sugarbaker, P. H. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.08.006 · Cited by 158 · cited 1×
“For example, in preclinical models, slower tumor growth rates and moderately increased tumor accumulation of oxaliplatin have been demonstrated with hyperthermia.(52,53) However, another study found no difference in the survival of CRC-bearing animals when cytoreductive surgery alone was compared with cytoreductive su…”
Fichtner, I., Slisow, W., Gill, J. H., Becker, M., Elbe, B., Hillebrand, T., & Bibby, M. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.10.011 · Cited by 156 · cited 1×
“Thus, results in preclinical studies seem to be variable and may be due to the specific model system studied, but at least in part may also represent the variability in response observed clinically.(51) Specific to this experiment, it is important to recognize that neither hyperthermia nor cytoreductive surgery was in…”
Elias, D. M., Matsuhisa, T., Sidéris, L., Liberale, G., Drouard-Troalen, L., Raynard, B., Pocard, M. D., Puizillou, J. M., Billard, V., Bourget, P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh398 · Cited by 136 · cited 4×
“Several groups have recently developed rat model systems incorporating both hyperthermia and cytoreductive surgery.52–55 For example, in preclinical models, slower tumor growth rates and moderately increased tumor accumulation of oxaliplatin have been demonstrated with hyperthermia.52,53 However, another study found n…”
InfluentialDrugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy
Kusamura, S., Elias, D. M., Baratti, D., Younan, R. J., & D, M. D. M. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21051 · Cited by 133
Yokoo, S., Masuda, S., Yonezawa, A., Terada, T., Katsura, T., & Inui, K. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023168 · Cited by 112 · cited 5×
“An initial experiment was undertaken to determine the efficacy of IP delivery of several chemotherapeutic drugs on survival of mice bearing peritoneally disseminated CRC.”
InfluentialKim, S.-H., Kwon, H.-C., Oh, S. Y., Lee, D. M., Lee, S., Lee, J., Roh, M.-S., Kim, D.-C., Park, K., Choi, H., et al. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31817be58e · Cited by 107 · cited 1×
“to oxaliplatin is related to expression of the excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) genes.(49,50) Therefore, similar to responsiveness to EGFR-targeted therapies, responsiveness of HT-29 cells to oxaliplatin may be related to cell-specific expression of OCT3, ERCC1, TS, or other…”
Balin-Gauthier, D., Delord, J., Rochaix, P., Mallard, V., Thomas, F., Hennebelle, I., Bugat, R., Canal, P., & Allal, B. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0123-3 · Cited by 105
Modulation of DNA Topoisomerase I Activity by p53
Gobert, C., Bracco, L., Rossi, F., Olivier, M., Tazi, J., Lavelle, F., Larsen, A. K., & Riou, J.-F. (1996) · Biochemistry · doi:10.1021/bi952327w · Cited by 102 · cited 1×
“can upregulate topoisomerase I, the target of irinotecan, and thus in combination, mitomycin C may function to sensitize the cancer cells to the effects of irinotecan.(67) Two phase I trials, one for solid tumors and one for advanced breast cancer, suggest improved survival and efficacy with systemic administration of…”
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2008) · AACR Education book · doi:10.1158/aacr.edb-ccr-06-1554 · Cited by 99
Ceelen, W. P., Peeters, M., Houtmeyers, P., Breusegem, C., Somer, F. M. J. J. D., & Pattyn, P. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9648-5 · Cited by 91
NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model
Cusack, J. C., Liu, R., Xia, L., Chao, T.-H., Pien, C., Niu, W., Palombella, V. J., Neuteboom, S. T. C., & Palladino, M. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1151 · Cited by 90
Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies
Pestieau, S. R., Belliveau, J. F., Griffin, H., Stuart, O. A., & Sugarbaker, P. H. (2001) · Journal of Surgical Oncology · doi:10.1002/1096-9098(200102)76:2<106::aid-jso1020>3.0.co;2-e · Cited by 84 · cited 1×
“For example, in preclinical models, slower tumor growth rates and moderately increased tumor accumulation of oxaliplatin have been demonstrated with hyperthermia.(52,53) However, another study found no difference in the survival of CRC-bearing animals when cytoreductive surgery alone was compared with cytoreductive su…”
Green, S. K., Karlsson, M. C. I., Ravetch, J. V., & Kerbel, R. S. (2002) · PubMed · Cited by 72
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
van Leeuwen, B. L., Graf, W. D., Påhlman, L., & Mahteme, H. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9700-5 · Cited by 70
Elias, D. M., Raynard, B., Bonnay, M., & Pocard, M. D. (2006) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2006.03.004 · Cited by 63 · cited 1×
“Limited reports thus far also indicate a favorable peritoneal pharmacokinetics and rapid conversion to SN-38 after IP administration of irinotecan in both clinical and preclinical settings.(20,65,66) At a cellular level, mitomycin C”
Moser, C., Lang, S. A., Kainz, S., Gaumann, A., Fichtner-Feigl, S., Koehl, G. E., Schlitt, H. J., Geissler, E. K., & Stoeltzing, O. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0410 · Cited by 63
Pharmacokinetic Characteristics of 5-Fluorouracil and Mitomycin C in Intraperitoneal Chemotherapy
Kuzuya, T., Yamauchi, M., Ito, A., Hasegawa, M., Hasegawa, T., & Nabeshima, T. (1994) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1994.tb03883.x · Cited by 62 · cited 1×
“Several studies have demonstrated favorable peritoneal to plasma area under the curve with both heated intraoperative and early postoperative IP mitomycin C administration.(62,63) Further, a lack of adequate exposure of malignant ascites to mitomycin C after intravenous administration has been shown.”
Correction: Prediction of Response to Cetuximab
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-16-cor1 · Cited by 54
Aarts, F., Hendriks, T., Boerman, O. C., Koppe, M. J., Oyen, W. J. G., & Bleichrodt, R. P. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9509-2 · Cited by 52 · cited 1×
“However, another study found no difference in the survival of CRC-bearing animals when cytoreductive surgery alone was compared with cytoreductive surgery with hyperthermic mitomycin C.(54) Another study assessing effects on tumor load found a marked effect of both HIPEC with mitomycin C and mitomycin C alone in reduc…”
Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
der Speeten, K. V., Stuart, O. A., & Sugarbaker, P. H. (2009) · Current Drug Discovery Technologies · doi:10.2174/157016309787581084 · Cited by 51 · cited 1×
“A pharmacokinetic advantage with IP delivery of several agents has been described.(57) Therapeutic advantage is likely due to multiple factors, including the transport of the drug”
Cavaliere, F., Valle, M., Simone, M. D., D, M. D. M., Rossi, C. R., Filippo, F. D., Verzi, S., Giannarelli, D., Perri, P., Pilati, P., et al. (2006) · PubMed · Cited by 49
Pelz, J. O. W., Doerfer, J., Hohenberger, W., & Meyer, T. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-56 · Cited by 48 · cited 3×
“Several groups have recently developed rat model systems incorporating both hyperthermia and cytoreductive surgery.52–55 For example, in preclinical models, slower tumor growth rates and moderately increased tumor accumulation of oxaliplatin have been demonstrated with hyperthermia.52,53 However, another study found n…”
Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer
Giuliani, F., Molica, S., Maiello, E., Battaglia, C., Gebbia, V., Bisceglie, M. D., Vinciarelli, G., Gebbia, N., & Colucci, G. (2005) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000190398.52142.7f · Cited by 45
Leonetti, C., Scarsella, M., Zupi, G., Zoli, W., Amadori, D., Medri, L., Fabbri, F., Rosetti, M., Ulivi, P., Cecconetto, L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0536 · Cited by 42
Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration
Sugarbaker, P. H., Stuart, O. A., Vidal-Jové, J., Pessagno, A., & DeBruijn, E. A. (1996) · Cancer treatment and research · doi:10.1007/978-1-4613-1247-5_3 · Cited by 41 · cited 1×
“Further, a lack of adequate exposure of malignant ascites to mitomycin C after intravenous administration has been shown.(64) Limited reports thus far also indicate a favorable peritoneal pharmacokinetics and rapid conversion to SN-38 after IP administration of irinotecan in both clinical and preclinical settings.”
Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses
Wildner, O., & Morris, J. C. (2000) · The Journal of Gene Medicine · doi:10.1002/1521-2254(200009/10)2:5<353::aid-jgm130>3.0.co;2-g · Cited by 41
Yang, X., Li, Y., Hassan, A. H. A.-S., Yang, G., Liu, S.-Y., Lu, Y., Zhang, J., & Yonemura, Y. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0226-2 · Cited by 40
Huang, Z.-H., Hua, D., Du, X., Li, L.-H., Mao, Y., Liu, Z.-H., Song, M.-X., & Zhou, X.-K. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6401 · Cited by 39 · cited 1×
“to oxaliplatin is related to expression of the excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) genes.(49,50) Therefore, similar to responsiveness to EGFR-targeted therapies, responsiveness of HT-29 cells to oxaliplatin may be related to cell-specific expression of OCT3, ERCC1, TS, or other…”
Nishino, K., Aoki, Y., Amikura, T., Obata, H., Sekine, M., Yahata, T., Fujita, K., & Tanaka, K. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.03.009 · Cited by 31
Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice.
Pearson, J. W., FitzGerald, D. J., Willingham, M. C., Wiltrout, R. H., Pastan, I. H., & Longo, D. L. (1989) · PubMed · Cited by 31
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts
Birle, D. C., & Hedley, D. W. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0504 · Cited by 31
Emerging therapies in gastrointestinal cancers
Nautiyal, J., Rishi, A. K., & Majumdar, A. P. N. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i46.7440 · Cited by 27
Bauer, T. W., Fan, F., Liu, W., Camp, E. R., Yang, A. D., Somcio, R., Bucana, C. D., Singh, R., & Ellis, L. M. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9486-5 · Cited by 25
Hribaschek, A., Pross, M., Kühn, R., Krüger, S., Ridwelski, K., Halangk, W., Boltze, C., & Lippert, H. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200207000-00007 · Cited by 21 · cited 2×
“In addition, positive effects of oxaliplatin treatment were observed when the drug was delivered before the development of macroscopic tumor seeds, but not after.(47) In comparison, the present study used a human CRC cell line and an immunoincompetent mouse system.”
Kimura, M., Konno, T., Miyamoto, Y., Kojima, Y., & Maeda, H. (1998) · PubMed · Cited by 19
Mitomycin as a modulator of irinotecan anticancer activity.
Villalona-Calero, M. A., & Kolesar, J. (2002) · PubMed · Cited by 17
Sugarbaker, P. H. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21078 · Cited by 16
Hribaschek, A., Kuhn, R., Pross, M., Meyer, F. P., Fahlke, J., Ridwelski, K., Boltze, C., & Lippert, H. (2005) · Surgery Today · doi:10.1007/s00595-004-3096-7 · Cited by 16 · cited 1×
“Limited reports thus far also indicate a favorable peritoneal pharmacokinetics and rapid conversion to SN-38 after IP administration of irinotecan in both clinical and preclinical settings.(20,65,66) At a cellular level, mitomycin C”
Le Page, S., Kwiatkowski, F., Paulin, C., Mohamed, F., Pezet, D., Chipponi, J., BENHAMED, M. A., Gilly, F. N., & Gléhen, O. (2006) · PubMed · Cited by 16
Epidermal growth factor receptor as a major anticancer drug target
Caponigro, F., Milano, A., Ottaiano, A., & Iaffaioli, R. V. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.6.877 · Cited by 13
Peritonectomy for Peritoneal Carcinomatosis: Long‐Term Outcomes from a Single Brazilian Institution
Akaishi, E. H., Teixeira, F., Katayama, M., Mizumoto, N., Costa, F. P., Buzaid, A. C., & Hoff, P. M. (2009) · World Journal of Surgery · doi:10.1007/s00268-008-9880-6 · Cited by 12
Yao, Y., Zhao, H., Sun, Y., Lin, F., Tang, L., & Chen, P. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.215.267 · Cited by 12
Ruan, H. H., Scott, K. R., Bautista, E., & Ammons, W. S. (2003) · Neoplasia · doi:10.1016/s1476-5586(03)80033-7 · Cited by 12
Denda, T., Ambo, T., Ohtsu, A., Yamada, Y., Shirao, K., Hyodo, I., & Arai, Y. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0604-1 · Cited by 10
Vasilevskaya, I. A., Selvakumaran, M., & O'Dwyer, P. J. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.044644 · Cited by 10
Rationale for mitomycin and irinotecan use in advanced breast cancer.
Xu, Y., & Shapiro, C. L. (2003) · PubMed · Cited by 5
Research works printed but not linked: 1
- Cavaliere F, Valle M, De Simone M, et al. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a SITILO multicentric study. In Vivo. 2006;20:747–50.
Cited by
Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M., Chua, T., Pelz, J., Baratti, D., Baumgartner, J. M., Berri, R., Bretcha-Boix, P., et al. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23728 · Cited by 163
“Irinotecan, MMC, and Panitumumab: at 120 days after cell injection, 100% of the tri‐agent therapy group survived [12].”
BackgroundAuer, R. C., Sivajohanathan, D., Biagi, J. J., Conner, J., Kennedy, E. D., & May, T. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.034 · Cited by 98
Noura, S., Ohue, M., Shingai, T., Kano, S., Ohigashi, H., Yano, M., Ishikawa, O., Takenaka, A., Murata, K., & Kameyama, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1319-2 · Cited by 54
“Furthermore, combination IP therapy with MMC, panitumumab, and irinotecan was superior to all other agents tested alone or in combination.(39) However, with regard to the combination IPC, further phase I clinical trials will be necessary to integrate into clinical practice.”
BackgroundSelection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer
Braam, H. J., Schellens, J. H. M., Boot, H., van Sandick, J. W., Knibbe, C. A. J., Boerma, D., & van Ramshorst, B. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.04.004 · Cited by 33
“The efficacy of intraperitoneal irinotecan has been demonstrated in several animal studies [88–91] In the largest study in humans no statistically significant difference was noted in survival after CRS + HIPEC using oxaliplatin with or without irinotecan in 146 colorectal patients with established…”
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series
Saif, M. W., Kontny, E., Syrigos, K., & Shahrokni, A. (2011) · Journal of Oncology · doi:10.1155/2011/125467 · Cited by 27
“Combined intraperitoneal chemotherapy of panitumumab, mitomycin-C, and irinotecan also showed efficacy in colorectal carcinomatosis in vivo [21].”
Background
Metadata
- Authors
- Cohen, M. S., Al-kasspooles, M. F., Williamson, S. K., Henry, D., Broward, M., & Roby, K. F.
- Affiliations
- University of Kansas Medical Center (US)
- Corresponding author
- Roby, Katherine F.
- Venue
- Annals of Surgical Oncology
- Published
- 2009-08-26
- Volume
- 17
- Issue
- 1
- Pages
- 296-303
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- OpenAlex
- W1966510780
- Cited by
- 17
- References
- 73
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 4
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Annals of Surgical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- intraperitoneal chemotherapy, combination chemotherapy, mitomycin C, oxaliplatin, irinotecan, panitumumab, cetuximab, erlotinib, FOLFIRI, cytoreduction, hyperthermic intraperitoneal chemotherapy, mouse model, overall survival
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Irinotecan, Oxaliplatin, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Injections, Intraperitoneal, Mice, Nude, Organoplatinum Compounds, Quinazolines, Tumor Cells, Cultured, Colorectal Neoplasms, Survival Rate, Mitomycin, Treatment Outcome, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.